318 related articles for article (PubMed ID: 25057883)
1. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
Kanbay M; Yilmaz MI; Apetrii M; Saglam M; Yaman H; Unal HU; Gok M; Caglar K; Oguz Y; Yenicesu M; Cetinkaya H; Eyileten T; Acikel C; Vural A; Covic A
Am J Nephrol; 2012; 36(3):228-37. PubMed ID: 22948239
[TBL] [Abstract][Full Text] [Related]
3. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
4. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D.
Wang XR; Yuan L; Zhang JJ; Hao L; Wang DG
Nephrology (Carlton); 2017 Apr; 22(4):286-292. PubMed ID: 27165564
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin: Another vascular calcification inhibitor?
Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
[TBL] [Abstract][Full Text] [Related]
6. Uremic toxicity and sclerostin in chronic kidney disease patients.
Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
[TBL] [Abstract][Full Text] [Related]
7. Renal elimination of sclerostin increases with declining kidney function.
Cejka D; Marculescu R; Kozakowski N; Plischke M; Reiter T; Gessl A; Haas M
J Clin Endocrinol Metab; 2014 Jan; 99(1):248-55. PubMed ID: 24187403
[TBL] [Abstract][Full Text] [Related]
8. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease.
Yilmaz MI; Siriopol D; Saglam M; Kurt YG; Unal HU; Eyileten T; Gok M; Cetinkaya H; Oguz Y; Sari S; Vural A; Mititiuc I; Covic A; Kanbay M
Kidney Int; 2014 Dec; 86(6):1213-20. PubMed ID: 24988065
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
[TBL] [Abstract][Full Text] [Related]
13. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
[TBL] [Abstract][Full Text] [Related]
14. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
[TBL] [Abstract][Full Text] [Related]
15. The relationship between IL-10 levels and cardiovascular events in patients with CKD.
Yilmaz MI; Solak Y; Saglam M; Cayci T; Acikel C; Unal HU; Eyileten T; Oguz Y; Sari S; Carrero JJ; Stenvinkel P; Covic A; Kanbay M
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1207-16. PubMed ID: 24789549
[TBL] [Abstract][Full Text] [Related]
16. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
[TBL] [Abstract][Full Text] [Related]
17. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
[TBL] [Abstract][Full Text] [Related]
18. Mean corpuscular volume is associated with endothelial dysfunction and predicts composite cardiovascular events in patients with chronic kidney disease.
Solak Y; Yilmaz MI; Saglam M; Demirbas S; Verim S; Unal HU; Gaipov A; Oguz Y; Kayrak M; Caglar K; Vural A; Turk S; Covic A; Kanbay M
Nephrology (Carlton); 2013 Nov; 18(11):728-35. PubMed ID: 23848392
[TBL] [Abstract][Full Text] [Related]
19. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
20. Effects of Cardiovascular Events on End-Stage Renal Disease and Mortality in Patients With Chronic Kidney Disease Before Dialysis.
Kuwahara M; Takehara E; Sasaki Y; Azetsu H; Kusaka K; Shikuma S; Akita W
Ther Apher Dial; 2016 Feb; 20(1):12-9. PubMed ID: 26679409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
